Erdogan-Trinkaus Ipek has filed 3 insider transactions across 1 company since December 2025.
Most recent transaction: a grant/award of 40655 shares of Eton Pharmaceuticals, Inc. ($ETON) on January 12, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 12, 2026 | Eton Pharmaceuticals, Inc. | $ETON | Erdogan-Trinkaus Ipek | Chief Commercial Officer | A | Employee Stock Option (Right to Buy) | 40655 | $0.00 | 123,878.0000 | 26,893,000 | 48.85% | 0.15% |
| Jan. 12, 2026 | Eton Pharmaceuticals, Inc. | $ETON | Erdogan-Trinkaus Ipek | Chief Commercial Officer | A | Restricted Stock Units | 25856 | $0.00 | 149,734.0000 | 26,893,000 | 20.87% | 0.10% |
| Dec. 12, 2025 | Eton Pharmaceuticals, Inc. | $ETON | Erdogan-Trinkaus Ipek | Chief Commercial Officer | F | Common Stock | 85 | $16.90 | 2,403.0000 | 26,893,000 | 3.42% | 0.00% |